A new trick for old science, and biotech VCs’ scrambled playbook
Stat News • 4/9/2026 – 4/10/2026
Summary
This week on "The Readout LOUD," the discussion focuses on the renewed interest in old exon science and the concerns unsettling biotech venture capitalists. Additionally, there is speculation about who will be the next CEO of PhRMA.
Advertisement
Lindy Score Breakdown (V4.2)
23h
Age
1
Sources
from cluster
7
Hours Since Seen
Final Score11/100
CategoryAntiLindy
StatusActive
Recency Multiplier90% (0.5^7/48)
Hero EligibleYes
Score BreakdownRisk 65
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 1 day(s) old - still early
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: A new trick for old science, and biotech VCs’ scrambled playbook
Stat News • Today
STAT+: Biotech VCs, used to a winning formula in drug development, face disruption
Stat News • 1 day ago
Opinion: What American hospitals can learn from India about waste
Stat News • 2 days ago
STAT+: Trump administration drops court fight to cap NIH payments for research overhead costs
Stat News • 1 day ago
STAT+: FDA rejects an industry proposal to deregulate some AI devices
Stat News • 1 day ago
Judge refuses to block sending abortion pill by mail for now, but says FDA must finish review
Stat News • 2 days ago
Opinion: How sports betting is hooking some young men
Stat News • 2 days ago
C-section rate in 2025 highest in a decade
Stat News • 1 day ago
How sports betting apps hook users
Stat News • Today
Opinion: I’m a MAHA activist. I went into the public health lion’s den — and it changed how I think
Stat News • Today